Platelets mediate oxidized low-density lipoprotein-induced monocyte extravasation and foam cell formation. 2014

Sigrun Badrnya, and Waltraud C Schrottmaier, and Julia B Kral, and Koon-Chu Yaiw, and Ivo Volf, and Gernot Schabbauer, and Cecilia Söderberg-Nauclér, and Alice Assinger
From the Institute of Physiology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria (S.B., W.C.S., J.B.K., I.V., G.S., A.A.); and Department of Medicine, Solna, Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden (K.-C.Y., C.S.-N., A.A.).

OBJECTIVE A growing body of evidence indicates that platelets contribute to the onset and progression of atherosclerosis by modulating immune responses. We aimed to elucidate the effects of oxidized low-density lipoprotein (OxLDL) on platelet-monocyte interactions and the consequences of these interactions on platelet phagocytosis, chemokine release, monocyte extravasation, and foam cell formation. RESULTS Confocal microscopy and flow cytometric analysis revealed that in vitro and in vivo stimulation with OxLDL resulted in rapid formation of platelet-monocyte aggregates, with a preference for CD16+ monocyte subsets. This platelet-monocyte interaction facilitated OxLDL uptake by monocytes, in a process that involved platelet CD36-OxLDL interaction, release of chemokines, such as CXC motif ligand 4, direct platelet-monocyte interaction, and phagocytosis of platelets. Inhibition of cyclooxygenase with acetylsalicylic acid and antagonists of ADP receptors, P2Y1 and P2Y12, partly abrogated OxLDL-induced platelet-monocyte aggregates and platelet-mediated lipid uptake in monocytes. Platelets also enhanced OxLDL-induced monocyte transmigration across an endothelial monolayer via direct interaction with monocytes in a transwell assay. Importantly, in LDLR(-/-) mice, platelet depletion resulted in a significant decrease of peritoneal macrophage recruitment and foam cell formation in a thioglycollate-elicited peritonitis model. In platelet-depleted wild-type mice, transfusion of ex vivo OxLDL-stimulated platelets induced monocyte extravasation to a higher extent when compared with resting platelets. CONCLUSIONS Our results on OxLDL-mediated platelet-monocyte aggregate formation, which promoted phenotypic changes in monocytes, monocyte extravasation and enhanced foam cell formation in vitro and in vivo, provide a novel mechanism for how platelets potentiate key steps of atherosclerotic plaque development and plaque destabilization.

UI MeSH Term Description Entries
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D008297 Male Males
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D010538 Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs. Primary Peritonitis,Secondary Peritonitis,Peritonitis, Primary,Peritonitis, Secondary
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D010973 Platelet Adhesiveness The process whereby PLATELETS adhere to something other than platelets, e.g., COLLAGEN; BASEMENT MEMBRANE; MICROFIBRILS; or other "foreign" surfaces. Adhesiveness, Platelet,Adhesivenesses, Platelet,Platelet Adhesivenesses
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D010978 Platelet Factor 4 A CXC chemokine that is found in the alpha granules of PLATELETS. The protein has a molecular size of 7800 kDa and can occur as a monomer, a dimer or a tetramer depending upon its concentration in solution. Platelet factor 4 has a high affinity for HEPARIN and is often found complexed with GLYCOPROTEINS such as PROTEIN C. Antiheparin Factor,CXCL4 Chemokine,Chemokine CXCL4,Heparin Neutralizing Protein,PF4 (Platelet Factor 4),gamma-Thromboglobulin,CXCL4, Chemokine,Chemokine, CXCL4,gamma Thromboglobulin

Related Publications

Sigrun Badrnya, and Waltraud C Schrottmaier, and Julia B Kral, and Koon-Chu Yaiw, and Ivo Volf, and Gernot Schabbauer, and Cecilia Söderberg-Nauclér, and Alice Assinger
November 2021, Journal of cardiovascular pharmacology,
Sigrun Badrnya, and Waltraud C Schrottmaier, and Julia B Kral, and Koon-Chu Yaiw, and Ivo Volf, and Gernot Schabbauer, and Cecilia Söderberg-Nauclér, and Alice Assinger
January 2014, Biochemical and biophysical research communications,
Sigrun Badrnya, and Waltraud C Schrottmaier, and Julia B Kral, and Koon-Chu Yaiw, and Ivo Volf, and Gernot Schabbauer, and Cecilia Söderberg-Nauclér, and Alice Assinger
March 2018, Biomolecules & therapeutics,
Sigrun Badrnya, and Waltraud C Schrottmaier, and Julia B Kral, and Koon-Chu Yaiw, and Ivo Volf, and Gernot Schabbauer, and Cecilia Söderberg-Nauclér, and Alice Assinger
November 2022, Foods (Basel, Switzerland),
Sigrun Badrnya, and Waltraud C Schrottmaier, and Julia B Kral, and Koon-Chu Yaiw, and Ivo Volf, and Gernot Schabbauer, and Cecilia Söderberg-Nauclér, and Alice Assinger
October 2025, Molecular and cellular biochemistry,
Sigrun Badrnya, and Waltraud C Schrottmaier, and Julia B Kral, and Koon-Chu Yaiw, and Ivo Volf, and Gernot Schabbauer, and Cecilia Söderberg-Nauclér, and Alice Assinger
August 2010, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology,
Sigrun Badrnya, and Waltraud C Schrottmaier, and Julia B Kral, and Koon-Chu Yaiw, and Ivo Volf, and Gernot Schabbauer, and Cecilia Söderberg-Nauclér, and Alice Assinger
June 2022, Autoimmunity,
Sigrun Badrnya, and Waltraud C Schrottmaier, and Julia B Kral, and Koon-Chu Yaiw, and Ivo Volf, and Gernot Schabbauer, and Cecilia Söderberg-Nauclér, and Alice Assinger
March 2018, Biochimica et biophysica acta. Molecular basis of disease,
Sigrun Badrnya, and Waltraud C Schrottmaier, and Julia B Kral, and Koon-Chu Yaiw, and Ivo Volf, and Gernot Schabbauer, and Cecilia Söderberg-Nauclér, and Alice Assinger
January 1997, Journal of lipid research,
Sigrun Badrnya, and Waltraud C Schrottmaier, and Julia B Kral, and Koon-Chu Yaiw, and Ivo Volf, and Gernot Schabbauer, and Cecilia Söderberg-Nauclér, and Alice Assinger
April 2000, Biological & pharmaceutical bulletin,
Copied contents to your clipboard!